Kalaris Therapeutics Inc
KLRS8.340USD
-0.010-0.12%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
155.98M시가총액
손실P/E TTM
자세한 내용은 Kalaris Therapeutics Inc 회사
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Kalaris Therapeutics Inc 정보
종목 코드 KLRS
회사 이름Kalaris Therapeutics Inc
상장일Jul 30, 2020
CEOOxtoby (Andrew)
직원 수6
유형Ordinary Share
회계 연도 종료Jul 30
주소400 Connell Drive
도시BERKELEY HEIGHTS
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호07922
전화16502492727
웹사이트https://kalaristx.com/
종목 코드 KLRS
상장일Jul 30, 2020
CEOOxtoby (Andrew)
Kalaris Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Napoleone Ferrara, M.D.
Dr. Napoleone Ferrara, M.D.
Director
Director
504.00K
--
Mr. David L. Hallal
Mr. David L. Hallal
Executive Chairman of the Board
Executive Chairman of the Board
130.55K
+1519.00%
Dr. Matthew Feinsod, M.D.
Dr. Matthew Feinsod, M.D.
Chief Medical Officer
Chief Medical Officer
4.03K
+4030.00%
Mr. Brett R. Hagen
Mr. Brett R. Hagen
Chief Accounting Officer
Chief Accounting Officer
--
--
Dr. Morana Jovan-Embiricos, Ph.D.
Dr. Morana Jovan-Embiricos, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andrew Oxtoby
Mr. Andrew Oxtoby
Chief Executive Officer, Principal Executive Officer, Director
Chief Executive Officer, Principal Executive Officer, Director
--
--
Dr. Anthony P. Adamis, M.D.
Dr. Anthony P. Adamis, M.D.
Director
Director
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Director
Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Director
Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Napoleone Ferrara, M.D.
Dr. Napoleone Ferrara, M.D.
Director
Director
504.00K
--
Mr. David L. Hallal
Mr. David L. Hallal
Executive Chairman of the Board
Executive Chairman of the Board
130.55K
+1519.00%
Dr. Matthew Feinsod, M.D.
Dr. Matthew Feinsod, M.D.
Chief Medical Officer
Chief Medical Officer
4.03K
+4030.00%
Mr. Brett R. Hagen
Mr. Brett R. Hagen
Chief Accounting Officer
Chief Accounting Officer
--
--
Dr. Morana Jovan-Embiricos, Ph.D.
Dr. Morana Jovan-Embiricos, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andrew Oxtoby
Mr. Andrew Oxtoby
Chief Executive Officer, Principal Executive Officer, Director
Chief Executive Officer, Principal Executive Officer, Director
--
--
수익 분석
FY2021
FY2020
FY2019
기업이 아직 관련 데이터를 공개하지 않았습니다.
지역별USD
이름
수익
비율
United States
0.00
0.00%
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Fri, Feb 6
마지막 업데이트: Fri, Feb 6
주주
주주 유형
주주
주주
비율
Samsara BioCapital, LLC
69.23%
ElevateBio LLC
3.88%
Ferrara (Napoleone)
2.69%
F2 MG Ltd
2.28%
Tang Capital Management, LLC
2.24%
기타
19.68%
주주
주주
비율
Samsara BioCapital, LLC
69.23%
ElevateBio LLC
3.88%
Ferrara (Napoleone)
2.69%
F2 MG Ltd
2.28%
Tang Capital Management, LLC
2.24%
기타
19.68%
주주 유형
주주
비율
Venture Capital
69.70%
Individual Investor
6.43%
Corporation
6.16%
Investment Advisor
4.81%
Hedge Fund
4.35%
Investment Advisor/Hedge Fund
1.42%
기타
7.12%
기관 주식 보유
마지막 업데이트: Wed, Jan 21
마지막 업데이트: Wed, Jan 21
보고 기간
기관 수
보유 주식
비율
변동
2026Q4
71
14.74M
71.45%
--
2025Q4
153
14.85M
79.41%
+821.65K
2025Q3
193
13.23M
70.72%
-1.05M
2025Q2
227
16.58M
88.66%
+10.64M
2025Q1
234
16.39M
87.75%
+10.95M
2024Q4
237
3.88M
53.28%
-1.58M
2024Q3
243
4.43M
85.21%
-1.20M
2024Q2
253
4.51M
86.91%
-1.04M
2024Q1
252
4.61M
89.02%
-783.99K
2023Q4
254
4.25M
88.46%
-716.47K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Samsara BioCapital, LLC
12.95M
69.23%
+1.50M
+13.10%
Dec 22, 2025
ElevateBio LLC
724.99K
3.88%
--
--
Jun 25, 2025
Ferrara (Napoleone)
504.00K
2.69%
--
--
Jun 25, 2025
F2 MG Ltd
427.31K
2.28%
-1.00
-0.00%
Jun 25, 2025
Tang Capital Management, LLC
418.24K
2.24%
+57.38K
+15.90%
Sep 30, 2025
Invus Public Equities Advisors, LLC
318.26K
1.7%
+35.68K
+12.63%
Sep 30, 2025
The Vanguard Group, Inc.
203.05K
1.09%
+73.21K
+56.39%
Sep 30, 2025
Patel (Samirbhai Chandrakant)
252.00K
1.35%
+252.00K
--
Mar 18, 2025
Woodline Partners LP
241.10K
1.29%
+241.10K
--
Sep 30, 2025
Rezai (Kourous)
203.67K
1.09%
+203.67K
--
Jun 25, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Value ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Equity ETF
0%
Proshares Ultra Russell 2000
0%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
Schwab U.S. Broad Market ETF
0%
ProShares UltraPro Russell2000
0%
더 보기
iShares Micro-Cap ETF
비율0.01%
iShares Russell 2000 Value ETF
비율0%
Fidelity Enhanced Small Cap ETF
비율0%
iShares Russell 2000 ETF
비율0%
Avantis US Equity ETF
비율0%
Proshares Ultra Russell 2000
비율0%
Avantis US Small Cap Equity ETF
비율0%
ProShares Hedge Replication ETF
비율0%
Schwab U.S. Broad Market ETF
비율0%
ProShares UltraPro Russell2000
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Jan 10, 2025
Merger
23→1
날짜
배당락일
유형
비율
Jan 10, 2025
Merger
23→1
